B.Riley on Opus Genetics (IRD): 'we remain buyers'

July 6, 2026 12:05 PM EDT Send to a Friend
B.Riley analyst Mayank Mamtani reiterated a Buy rating and $10.00 price target on Opus Genetics (NASDAQ: IRD).The analyst comments "Following ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login